The Latin America, Middle East and Africa Lysosomal Disease Treatment Market would witness market growth of 12.7% CAGR during the forecast period (2022-2028).
The nervous system exhibits particularly high levels of ganglioside expression, and gangliosides are neurodegenerative disorders. Skeletal tissue expresses keratan and dermatan sulfate at high levels, and mucopolysaccharidoses, which have deficiencies in their breakdown mechanisms, are characterized by problem-related multiplex severe abnormalities in the development of skeletal cartilage and bone. Within each ailment, there is also a great deal of variety, from severe, infantile-onset types to attenuated adult-onset diseases, sometimes with different clinical symptoms. It would make sense to say that this variance is a byproduct of the residual activity of the relevant metabolic pathway.
Since total enzyme deficiency is incompatible with extra-uterine life, it causes hydrops fetalis and the collodion infant phenotype, for instance, in Gaucher disease. Where there is little enzyme activity, storage happens quickly in several tissues, including neurons, leading to the quickly lethal juvenile neuronopathic phenotype (type 2 illness). For most tissues, even a little amount of residual activity can stop accumulation and stop neurodegeneration.
As lifestyle problems become more common, these relatively wealthy people would continue to look for more expensive healthcare. The government has focused on creating a healthcare infrastructure to satisfy this need. In the United Arab Emirates, healthcare is governed by both the federal and provincial governments. The Health and Prevention Ministry is the most important government regulating organization for the healthcare sector in the UAE. To encourage foreign investment and raise the standard of healthcare in the country, the UAE government is easing regulations that boosts the growth of the lysosomal disease treatment market in this region.
The Brazil market dominated the LAMEA Lysosomal Disease Treatment Market by Country in 2021, thereby, achieving a market value of $235.1 Million by 2028. The Argentina market is obtained to grow at a CAGR of 13.3% during (2022 - 2028). Additionally, The UAE market is experiencing a CAGR of 12.4% during (2022 - 2028).
Based on Disease Type, the market is segmented into Gaucher's Diseases, Fabry Diseases, Mucopolysaccharidosis, Pompe’s Syndrome and Others. Based on Type of Therapy, the market is segmented into Enzyme Replacement Therapy, Substrate Reduction Therapy, Stem Cell Therapy and Others. Based on End User, the market is segmented into Hospitals, Clinics and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Lysosomal Disease Treatment Market is Predict to reach $11 Billion by 2028, at a CAGR of 6.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC), Eli Lilly And Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Sanofi S.A., Novartis AG, AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), BioMarin Pharmaceutical Inc. and Sigilon Therapeutics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Disease Type
- Gaucher's Diseases
- Fabry Diseases
- Mucopolysaccharidosis
- Pompe’s Syndrome
- Others
By Type of Therapy
- Enzyme Replacement Therapy
- Substrate Reduction Therapy
- Stem Cell Therapy
- Others
By End User
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Merck & Co., Inc.
- Johnson & Johnson (Janssen Global Services, LLC)
- Eli Lilly And Company
- Pfizer, Inc.
- Takeda Pharmaceutical Company Limited
- Sanofi S.A.
- Novartis AG
- AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
- BioMarin Pharmaceutical Inc.
- Sigilon Therapeutics, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Lysosomal Disease Treatment Market, by Disease Type
1.4.2 LAMEA Lysosomal Disease Treatment Market, by Type of Therapy
1.4.3 LAMEA Lysosomal Disease Treatment Market, by End User
1.4.4 LAMEA Lysosomal Disease Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Lysosomal Disease Treatment Market by Disease Type
3.1 LAMEA Gaucher's Diseases Market by Country
3.2 LAMEA Fabry Diseases Market by Country
3.3 LAMEA Mucopolysaccharidosis Market by Country
3.4 LAMEA Pompe’s Syndrome Market by Country
3.5 LAMEA Others Market by Country
Chapter 4. LAMEA Lysosomal Disease Treatment Market by Type of Therapy
4.1 LAMEA Enzyme Replacement Therapy Market by Country
4.2 LAMEA Substrate Reduction Therapy Market by Country
4.3 LAMEA Stem Cell Therapy Market by Country
4.4 LAMEA Others Market by Country
Chapter 5. LAMEA Lysosomal Disease Treatment Market by End User
5.1 LAMEA Hospitals Market by Country
5.2 LAMEA Clinics Market by Country
5.3 LAMEA Others Market by Country
Chapter 6. LAMEA Lysosomal Disease Treatment Market by Country
6.1 Brazil Lysosomal Disease Treatment Market
6.1.1 Brazil Lysosomal Disease Treatment Market by Disease Type
6.1.2 Brazil Lysosomal Disease Treatment Market by Type of Therapy
6.1.3 Brazil Lysosomal Disease Treatment Market by End User
6.2 Argentina Lysosomal Disease Treatment Market
6.2.1 Argentina Lysosomal Disease Treatment Market by Disease Type
6.2.2 Argentina Lysosomal Disease Treatment Market by Type of Therapy
6.2.3 Argentina Lysosomal Disease Treatment Market by End User
6.3 UAE Lysosomal Disease Treatment Market
6.3.1 UAE Lysosomal Disease Treatment Market by Disease Type
6.3.2 UAE Lysosomal Disease Treatment Market by Type of Therapy
6.3.3 UAE Lysosomal Disease Treatment Market by End User
6.4 Saudi Arabia Lysosomal Disease Treatment Market
6.4.1 Saudi Arabia Lysosomal Disease Treatment Market by Disease Type
6.4.2 Saudi Arabia Lysosomal Disease Treatment Market by Type of Therapy
6.4.3 Saudi Arabia Lysosomal Disease Treatment Market by End User
6.5 South Africa Lysosomal Disease Treatment Market
6.5.1 South Africa Lysosomal Disease Treatment Market by Disease Type
6.5.2 South Africa Lysosomal Disease Treatment Market by Type of Therapy
6.5.3 South Africa Lysosomal Disease Treatment Market by End User
6.6 Nigeria Lysosomal Disease Treatment Market
6.6.1 Nigeria Lysosomal Disease Treatment Market by Disease Type
6.6.2 Nigeria Lysosomal Disease Treatment Market by Type of Therapy
6.6.3 Nigeria Lysosomal Disease Treatment Market by End User
6.7 Rest of LAMEA Lysosomal Disease Treatment Market
6.7.1 Rest of LAMEA Lysosomal Disease Treatment Market by Disease Type
6.7.2 Rest of LAMEA Lysosomal Disease Treatment Market by Type of Therapy
6.7.3 Rest of LAMEA Lysosomal Disease Treatment Market by End User
Chapter 7. Company Profiles
7.1 Merck & Co., Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Johnson & Johnson (Janssen Global Services, LLC)
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental &Regional Analysis
7.2.4 Research & Development Expenses
7.3 Eli Lilly And Company
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Acquisition and Mergers:
7.4 Pfizer, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.5 Takeda Pharmaceutical Company Limited
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expense
7.6 Sanofi S.A.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.7 Novartis AG
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.9 BioMarin Pharmaceutical Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Approvals and Trials:
7.10. Sigilon Therapeutics, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expenses
TABLE 1 LAMEA Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 2 LAMEA Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 3 LAMEA Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 4 LAMEA Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 5 LAMEA Gaucher's Diseases Market by Country, 2018 - 2021, USD Million
TABLE 6 LAMEA Gaucher's Diseases Market by Country, 2022 - 2028, USD Million
TABLE 7 LAMEA Fabry Diseases Market by Country, 2018 - 2021, USD Million
TABLE 8 LAMEA Fabry Diseases Market by Country, 2022 - 2028, USD Million
TABLE 9 LAMEA Mucopolysaccharidosis Market by Country, 2018 - 2021, USD Million
TABLE 10 LAMEA Mucopolysaccharidosis Market by Country, 2022 - 2028, USD Million
TABLE 11 LAMEA Pompe’s Syndrome Market by Country, 2018 - 2021, USD Million
TABLE 12 LAMEA Pompe’s Syndrome Market by Country, 2022 - 2028, USD Million
TABLE 13 LAMEA Others Market by Country, 2018 - 2021, USD Million
TABLE 14 LAMEA Others Market by Country, 2022 - 2028, USD Million
TABLE 15 LAMEA Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 16 LAMEA Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 17 LAMEA Enzyme Replacement Therapy Market by Country, 2018 - 2021, USD Million
TABLE 18 LAMEA Enzyme Replacement Therapy Market by Country, 2022 - 2028, USD Million
TABLE 19 LAMEA Substrate Reduction Therapy Market by Country, 2018 - 2021, USD Million
TABLE 20 LAMEA Substrate Reduction Therapy Market by Country, 2022 - 2028, USD Million
TABLE 21 LAMEA Stem Cell Therapy Market by Country, 2018 - 2021, USD Million
TABLE 22 LAMEA Stem Cell Therapy Market by Country, 2022 - 2028, USD Million
TABLE 23 LAMEA Others Market by Country, 2018 - 2021, USD Million
TABLE 24 LAMEA Others Market by Country, 2022 - 2028, USD Million
TABLE 25 LAMEA Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 26 LAMEA Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 27 LAMEA Hospitals Market by Country, 2018 - 2021, USD Million
TABLE 28 LAMEA Hospitals Market by Country, 2022 - 2028, USD Million
TABLE 29 LAMEA Clinics Market by Country, 2018 - 2021, USD Million
TABLE 30 LAMEA Clinics Market by Country, 2022 - 2028, USD Million
TABLE 31 LAMEA Others Market by Country, 2018 - 2021, USD Million
TABLE 32 LAMEA Others Market by Country, 2022 - 2028, USD Million
TABLE 33 LAMEA Lysosomal Disease Treatment Market by Country, 2018 - 2021, USD Million
TABLE 34 LAMEA Lysosomal Disease Treatment Market by Country, 2022 - 2028, USD Million
TABLE 35 Brazil Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 36 Brazil Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 37 Brazil Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 38 Brazil Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 39 Brazil Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 40 Brazil Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 41 Brazil Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 42 Brazil Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 43 Argentina Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 44 Argentina Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 45 Argentina Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 46 Argentina Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 47 Argentina Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 48 Argentina Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 49 Argentina Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 50 Argentina Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 51 UAE Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 52 UAE Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 53 UAE Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 54 UAE Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 55 UAE Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 56 UAE Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 57 UAE Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 58 UAE Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 59 Saudi Arabia Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 60 Saudi Arabia Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 61 Saudi Arabia Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 62 Saudi Arabia Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 63 Saudi Arabia Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 64 Saudi Arabia Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 65 Saudi Arabia Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 66 Saudi Arabia Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 67 South Africa Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 68 South Africa Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 69 South Africa Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 70 South Africa Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 71 South Africa Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 72 South Africa Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 73 South Africa Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 74 South Africa Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 75 Nigeria Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 76 Nigeria Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 77 Nigeria Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 78 Nigeria Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 79 Nigeria Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 80 Nigeria Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 81 Nigeria Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 82 Nigeria Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 83 Rest of LAMEA Lysosomal Disease Treatment Market, 2018 - 2021, USD Million
TABLE 84 Rest of LAMEA Lysosomal Disease Treatment Market, 2022 - 2028, USD Million
TABLE 85 Rest of LAMEA Lysosomal Disease Treatment Market by Disease Type, 2018 - 2021, USD Million
TABLE 86 Rest of LAMEA Lysosomal Disease Treatment Market by Disease Type, 2022 - 2028, USD Million
TABLE 87 Rest of LAMEA Lysosomal Disease Treatment Market by Type of Therapy, 2018 - 2021, USD Million
TABLE 88 Rest of LAMEA Lysosomal Disease Treatment Market by Type of Therapy, 2022 - 2028, USD Million
TABLE 89 Rest of LAMEA Lysosomal Disease Treatment Market by End User, 2018 - 2021, USD Million
TABLE 90 Rest of LAMEA Lysosomal Disease Treatment Market by End User, 2022 - 2028, USD Million
TABLE 91 KEY INFORMATION - MERCK & CO., INC.
TABLE 92 Key information –Johnson & Johnson
TABLE 93 Key Information – Eli Lilly And Company
TABLE 94 Key Information – Pfizer, Inc.
TABLE 95 Key Information – Takeda Pharmaceutical Company Limited
TABLE 96 Key Information – Sanofi S.A.
TABLE 97 Key Information – Novartis AG
TABLE 98 KEY INFORMATION – ASTRAZENECA PLC
TABLE 99 Key Information – BioMarin Pharmaceutical Inc.
TABLE 100 Key Information – Sigilon Therapeutics, Inc.
List of Figures
FIG 1 Methodology for the research